相似文献
1
Role of progesterone in endometrial cancer.
Semin Reprod Med. 2010 Jan;28(1):81-90. doi: 10.1055/s-0029-1242998. Epub 2010 Jan 26.
2
Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer.
Am J Obstet Gynecol. 2021 Oct;225(4):407.e1-407.e16. doi: 10.1016/j.ajog.2021.05.007. Epub 2021 May 19.
3
Molecular tools to reestablish progestin control of endometrial cancer cell proliferation.
Am J Obstet Gynecol. 2001 Apr;184(5):790-7. doi: 10.1067/mob.2001.113844.
4
Influence of AKT on progesterone action in endometrial diseases.
Biol Reprod. 2014 Sep;91(3):63. doi: 10.1095/biolreprod.114.119255. Epub 2014 Aug 6.
5
A functional role of LEFTY during progesterone therapy for endometrial carcinoma.
Cell Commun Signal. 2017 Dec 21;15(1):56. doi: 10.1186/s12964-017-0211-0.
6
7
Progesterone: the ultimate endometrial tumor suppressor.
Trends Endocrinol Metab. 2011 Apr;22(4):145-52. doi: 10.1016/j.tem.2011.01.005. Epub 2011 Feb 25.
8
Up-regulation and nuclear localization of beta-catenin in endometrial carcinoma in response to progesterone therapy.
Cancer Sci. 2003 Jan;94(1):103-11. doi: 10.1111/j.1349-7006.2003.tb01360.x.
9
Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA. 1996 Feb 7;275(5):370-5. doi: 10.1001/jama.1996.03530290040035.
10
Endometrial Cancer-Associated FGF18 Expression Is Reduced by Bazedoxifene in Human Endometrial Stromal Cells In Vitro and in Murine Endometrium.
Endocrinology. 2016 Oct;157(10):3699-3708. doi: 10.1210/en.2016-1233. Epub 2016 Jun 6.
引用本文的文献
1
The role of the microbiome in endometrial carcinoma: Pathogenesis, biomarkers, and therapeutic prospects.
J Obstet Gynaecol Res. 2025 Sep;51(9):e70070. doi: 10.1111/jog.70070.
2
Female Reproductive Tract Organoids: Applications from Physiology to Pathology.
Biomolecules. 2025 Jun 24;15(7):925. doi: 10.3390/biom15070925.
3
Endometrial thickness among BRCA mutation carriers undergoing prophylactic oophorectomy.
Fam Cancer. 2025 Mar 25;24(2):32. doi: 10.1007/s10689-025-00458-8.
4
Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial Cancer.
Cancers (Basel). 2025 Feb 10;17(4):598. doi: 10.3390/cancers17040598.
5
Association of Pregnancy Complications with Endometrial or Ovarian or Breast Cancer: A Case Control Study.
Medicina (Kaunas). 2024 Dec 24;61(1):1. doi: 10.3390/medicina61010001.
6
Uterine-Conserving Treatment Options for Atypical Endometrial Hyperplasia and Early Endometrial Cancer.
Curr Oncol Rep. 2024 Nov;26(11):1367-1379. doi: 10.1007/s11912-024-01603-9. Epub 2024 Oct 3.
7
Reproductive and transcriptome characteristics of endometrium at the window of im-plantation in patients after fertility-sparing treatment of endometrial intraepithelial neoplasm or cancer.
Heliyon. 2024 Aug 17;10(16):e36329. doi: 10.1016/j.heliyon.2024.e36329. eCollection 2024 Aug 30.
8
Advances in research on autophagy mechanisms in resistance to endometrial cancer treatment.
Front Oncol. 2024 Mar 27;14:1364070. doi: 10.3389/fonc.2024.1364070. eCollection 2024.
9
Phosphorylation of IDH1 Facilitates Progestin Resistance in Endometrial Cancer.
Adv Sci (Weinh). 2024 Jun;11(23):e2310208. doi: 10.1002/advs.202310208. Epub 2024 Apr 6.
10
Role of microRNA in Sex Steroid Hormones Signaling and Its Effect in Regulation of Endometrial, Ovarian, and Cervical Cancer: A Literature Review.
Cureus. 2024 Feb 23;16(2):e54773. doi: 10.7759/cureus.54773. eCollection 2024 Feb.
本文引用的文献
1
Progesterone induces nano-scale molecular modifications on endometrial epithelial cell surfaces.
Biol Cell. 2009 Jun 4;101(8):481-93. doi: 10.1042/BC20080189.
2
Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
Gynecol Oncol. 2009 Mar;112(3):537-42. doi: 10.1016/j.ygyno.2008.10.032. Epub 2008 Dec 23.
3
Sparing fertility in young patients with endometrial cancer.
Gynecol Oncol. 2008 Nov;111(2 Suppl):S101-4. doi: 10.1016/j.ygyno.2008.07.056. Epub 2008 Sep 18.
4
Systematic expression analysis and antibody screening do not support the existence of naturally occurring progesterone receptor (PR)-C, PR-M, or other truncated PR isoforms.
Endocrinology. 2008 Nov;149(11):5872-87. doi: 10.1210/en.2008-0602. Epub 2008 Jul 10.
5
The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study.
Eur J Obstet Gynecol Reprod Biol. 2008 Aug;139(2):169-75. doi: 10.1016/j.ejogrb.2008.02.022. Epub 2008 Apr 28.
6
Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system.
Obstet Gynecol. 2008 Feb;111(2 Pt 2):547-9. doi: 10.1097/01.AOG.0000300716.84819.c6.
7
Glycodelin blocks progression to S phase and inhibits cell growth: a possible progesterone-induced regulator for endometrial epithelial cell growth.
Mol Hum Reprod. 2008 Jan;14(1):17-22. doi: 10.1093/molehr/gam081. Epub 2008 Jan 4.
8
The regulation and function of the forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma.
Endocrinology. 2008 Apr;149(4):1942-50. doi: 10.1210/en.2007-0756. Epub 2007 Dec 20.
9
Progesterone-mediated regulation of catechol-O-methyl transferase expression in endometrial cancer cells.
Reprod Sci. 2008 Feb;15(2):210-20. doi: 10.1177/1933719107310398. Epub 2007 Dec 18.
10
Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone.
Steroids. 2008 Jan;73(1):116-28. doi: 10.1016/j.steroids.2007.09.010. Epub 2007 Oct 12.
Zotero 插件